416 related articles for article (PubMed ID: 24638121)
1. Comparison of SEER Treatment Data With Medicare Claims.
Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL
Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121
[TBL] [Abstract][Full Text] [Related]
2. Validation of electronic data on chemotherapy and hormone therapy use in HMOs.
Ritzwoller DP; Carroll N; Delate T; O'Keeffe-Rossetti M; Fishman PA; Loggers ET; Aiello Bowles EJ; Elston-Lafata J; Hornbrook MC
Med Care; 2013 Oct; 51(10):e67-73. PubMed ID: 22531648
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis date agreement between SEER and Medicare claims data: impact on treatment.
Lin CC; Virgo KS
Med Care; 2014 Jan; 52(1):32-7. PubMed ID: 24322987
[TBL] [Abstract][Full Text] [Related]
4. Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries.
Walker GV; Giordano SH; Williams M; Jiang J; Niu J; MacKinnon J; Anderson P; Wohler B; Sinclair AH; Boscoe FP; Schymura MJ; Buchholz TA; Smith BD
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):686-93. PubMed ID: 23773392
[TBL] [Abstract][Full Text] [Related]
5. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
[TBL] [Abstract][Full Text] [Related]
6. Age disparity in palliative radiation therapy among patients with advanced cancer.
Wong J; Xu B; Yeung HN; Roeland EJ; Martinez ME; Le QT; Mell LK; Murphy JD
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):224-30. PubMed ID: 25195994
[TBL] [Abstract][Full Text] [Related]
7. Utility of the SEER-Medicare data to identify chemotherapy use.
Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB
Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169
[TBL] [Abstract][Full Text] [Related]
8. Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
Fang P; He W; Gomez DR; Hoffman KE; Smith BD; Giordano SH; Jagsi R; Smith GL
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):748-757. PubMed ID: 28366580
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Completeness of Managed Care Data to Identify Cancer Diagnoses and Treatments for Patients in the SEER-Medicare Data.
Warren JL; Parsons HM; Mariotto AB; Boyd E; Enewold L
Med Care; 2023 Dec; 61(12):846-857. PubMed ID: 37796197
[TBL] [Abstract][Full Text] [Related]
10. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
[TBL] [Abstract][Full Text] [Related]
12. Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
Wang K; Sheets NC; Basak R; Chen RC
Cancer; 2016 Oct; 122(19):3069-74. PubMed ID: 27352280
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
14. Assessing Cancer Treatment Information Using Medicare and Hospital Discharge Data among Women with Non-Hodgkin Lymphoma in a Los Angeles County Case-Control Study.
Zhong C; Seibold P; Chao CR; Cozen W; Song JY; Weisenburger D; Bernstein L; Wang SS
Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):936-941. PubMed ID: 32066614
[TBL] [Abstract][Full Text] [Related]
15. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer.
Onukwugha E; Yong C; Hussain A; Seal B; Mullins CD
BMC Med Res Methodol; 2014 Jan; 14():1. PubMed ID: 24383436
[TBL] [Abstract][Full Text] [Related]
16. A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program.
Mettlin CJ; Menck HR; Winchester DP; Murphy GP
Cancer; 1997 May; 79(10):2052-61. PubMed ID: 9149035
[TBL] [Abstract][Full Text] [Related]
17. Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations.
Williams CD; Alpert N; Redding TS; Bullard AJ; Flores RM; Kelley MJ; Taioli E
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):112-118. PubMed ID: 31624076
[TBL] [Abstract][Full Text] [Related]
18. Identifying specific chemotherapeutic agents in Medicare data: a validation study.
Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL
Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.
Fleming ST; Hamilton AS; Sabatino SA; Kimmick GG; Wu XC; Owen JB; Huang B; Hwang W;
Med Care; 2014 Sep; 52(9):e58-64. PubMed ID: 23222532
[TBL] [Abstract][Full Text] [Related]
20. The utility of Medicare claims data for measuring cancer stage.
Cooper GS; Yuan Z; Stange KC; Amini SB; Dennis LK; Rimm AA
Med Care; 1999 Jul; 37(7):706-11. PubMed ID: 10424641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
